InvestorsHub Logo
icon url

BonelessCat

07/01/12 3:06 AM

#2978 RE: Ovidius #2977

Buy out value will be after completion of the first phase trial for at least one of the two lead drugs, or possibly both, and will be based on market potential minus the cost of completion for market approval minus the estimated time and cost remaining to market.

IMO, effective psoriasis treatment = $3 billion to $7 billion and effective Kevetrin = similar value

Total $6 - $14 billion. I get a lot of money left over after subtracting time, cost, and likelihood for failure/approval.

Any buy out price will be disconnected from market pps, unless it runs to double-digit numbers first.
icon url

govorchin

07/01/12 10:28 AM

#2980 RE: Ovidius #2977

it is true the company is broke. it is also true that the two running the company are not broke and already have big big buccks inv ested in it. not likely to let it sink now. imo